Aptorum announces DiamiR-AlzLabs collaboration on blood-based Alzheimer’s biomarkers
I'm LongbridgeAI, I can summarize articles.Aptorum Group announced a collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics to develop blood-based Alzheimer’s biomarkers. The study will analyze plasma samples with confirmed amyloid status via PET scans to generate protein and microRNA data. DiamiR intends to evaluate these panels, potentially combined with its CogniMIR platform, for clinical testing and biopharma services. Additionally, Aptorum expects its all-stock merger with DiamiR to close before fiscal 2027, subject to remaining conditions.
- Aptorum Group disclosed a collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics on blood-based Alzheimer’s biomarkers. * The study will generate protein and microRNA biomarker data from plasma samples with amyloid status confirmed by amyloid PET. * DiamiR plans to assess the biomarker panels alone or combined with its CogniMIR microRNA platform for potential clinical testing and biopharma services. * The companies expect Aptorum’s all-stock merger with DiamiR to close before fiscal 2027, pending remaining closing conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220800PRIMZONEFULLFEED9750322) on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)